LMRI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lumexa Imaging Holdings Inc (LMRI) is not a strong buy at this moment for a beginner investor with a long-term focus. While the company shows potential for growth in the diagnostic imaging market and has positive analyst ratings, the technical indicators suggest a bearish trend, and the stock is currently oversold. Additionally, the recent financial performance, despite revenue growth, includes significant net losses, which could deter long-term investors. The absence of strong trading signals or recent congressional trading data further supports a hold recommendation.
The technical indicators for LMRI are bearish. The MACD is negatively expanding (-0.484), the RSI is at 10.5, indicating an oversold condition, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 8.633 and S2 at 7.177, suggesting potential further downside.
Analysts have a positive outlook on LMRI, with multiple firms rating it as a Buy or Strong Buy and price targets ranging from $22 to $
The company is the second-largest independent diagnostic testing facility operator in the U.S. and benefits from secular tailwinds in the imaging market.
Revenue increased by 7.95% YoY in Q4 2025, and adjusted EBITDA grew by 18.6%, showing operational improvements.
The company reported a significant net loss of $28.7 million in Q4 2025, which has raised concerns about profitability.
Investigation by Johnson Fistel for potential violations of federal securities laws could impact investor sentiment.
Technical indicators suggest a bearish trend, and the stock is currently oversold.
In Q4 2025, Lumexa Imaging reported a revenue increase of 7.95% YoY to $267.7 million, adjusted EBITDA growth of 18.6%, and a significant reduction in leverage. However, the company also reported a net loss of $28.7 million, an EPS of -0.38 (up 46.15% YoY), and a gross margin increase to 11.1%, up 134.18% YoY. While there are signs of operational improvement, the net loss remains a concern.
Analysts are generally bullish on LMRI. Raymond James recently upgraded the stock to Strong Buy with a $23 price target, citing valuation and growth potential. Other firms, including Deutsche Bank, Barclays, Jefferies, Wells Fargo, and Leerink, have initiated coverage with Buy or Overweight ratings and price targets ranging from $22 to $23. Analysts highlight the company's strong local market position, secular tailwinds, and growth drivers such as new center openings and advanced imaging mix.
